• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email
    SC 13G/A 1 lilly241106_sc13ga.htm SC 13G/A

     

         
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     
         
     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 40)

     

     

     
      Eli Lilly and Company  
     

     

    (Name of Issuer)

    Common Stock, Without Par Value

     
     

     

    (Title of Class of Securities)

    532457-10-8

     
     

     

    (CUSIP Number)

    September 30, 2024

     
     

     

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

     

    o Rule 13d-1(c)

     

    ü Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

    1 of 5

     

     

    CUSIP No. 532457-10-8 13G  

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

    LILLY ENDOWMENT INC.

    35-0868122

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    INDIANA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

    5

    SOLE VOTING POWER

    96,891,978

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    96,891,978

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    96,891,978

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    10.20%

    12

    TYPE OF REPORTING PERSON

    CO

           

     Footnote:

    The percent of class represented is based on 950,425,778 shares of common stock outstanding as of August 5, 2024, as reported on the Issuer's Form 10-Q for the period ended June 30, 2024.

    2 of 5

     

    Item 1.

    (a)Name of Issuer

    Eli Lilly and Company

     

    (b)Address of Issuer's Principal Executive Offices

    Lilly Corporate Ctr, Drop Code 1094

    Indianapolis, Indiana, 46285

     

     

    Item 2.

    (a)Name of Person Filing

    This statement is filed by Lilly Endowment Inc., a not for profit corporation organized under the laws of the State of Indiana. Lilly Endowment Inc. is an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986 and is a private foundation under Section 509(a) of the Code.

     

    (b)Address of Principal Business Office or, if none, Residence

    The address of the principal business office of Lilly Endowment Inc. is 2801 North Meridian Street, Indianapolis, Indiana 46208.

     

     

    (c)Citizenship

    Indiana

     

    (d)Title of Class of Securities

    Common Stock, Without Par Value

     

    (e)CUSIP Number

    532457-10-8

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
         
     (b)o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c):
         
     (c)o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
         
     (d)o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
         
     (e)o An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
         
     (f)o An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
         
     (g)o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         
     (h)o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
     (i)o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the
    Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
     (j)o Group, in accordance with§ 240.13d-l(b)(I)(ii)(J).

    3 of 5

     

     

    Item 4.Ownership

     

    (a)Amount Beneficially Owned
       
      96,891,978

     

    (b)Percent of Class
       
      10.20%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote
         
        96,891,978
         
       (ii) Shared power to vote or to direct the vote
         
        0
         
       (iii)Sole power to dispose or to direct the disposition of
         
        96,891,978
         
       (iv) Shared power to dispose or to direct the disposition of
         
        0

     

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9.Notice of Dissolution of Group

    Not Applicable

     

    Item 10.Certification

     

    Not Applicable

    4 of 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 21, 2024 Lilly Endowment Inc.
       
      By: /s/ Diane M. Stenson
      Name: Diane M. Stenson
      Title: Vice President & Treasurer

     

    Footnotes: Item 4: This information is provided as of September 30, 2024.
       
      Item 4(a): None of such shares are deemed to be beneficially owned by reason of the possession of Lilly Endowment Inc. of a right to acquire such shares.
       
      Item 4(b): The percent of class represented is based on shares of common stock outstanding as of August 5, 2024, as reported on the Issuer's Form 10-Q for the period ended June 30, 2024.

     

    5 of 5 

    Get the next $LLY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LLY

    DatePrice TargetRatingAnalyst
    4/28/2025$1150.00 → $700.00Buy → Reduce
    HSBC Securities
    4/22/2025$975.00Overweight
    Cantor Fitzgerald
    12/10/2024$997.00Buy
    BofA Securities
    11/15/2024$1000.00Outperform
    Wolfe Research
    10/17/2024$1100.00Outperform
    Bernstein
    9/13/2024$1060.00Buy
    Citigroup
    8/12/2024$1025.00Hold → Buy
    Deutsche Bank
    2/21/2024$820.00Buy → Hold
    DZ Bank
    More analyst ratings

    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, GC & Secretary Hakim Anat gifted 17,875 shares, decreasing direct ownership by 62% to 10,962 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      5/5/25 4:17:08 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sulzberger Gabrielle was granted 6 shares, increasing direct ownership by 0.24% to 2,562 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      4/22/25 4:22:49 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Luciano Juan R was granted 18 shares, increasing direct ownership by 0.11% to 16,294 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      4/22/25 4:21:20 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    SEC Filings

    See more
    • Eli Lilly and Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ELI LILLY & Co (0000059478) (Filer)

      5/8/25 4:34:55 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Eli Lilly and Company

      10-Q - ELI LILLY & Co (0000059478) (Filer)

      5/1/25 11:30:18 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eli Lilly and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ELI LILLY & Co (0000059478) (Filer)

      5/1/25 7:03:11 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eli Lilly downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Eli Lilly from Buy to Reduce and set a new price target of $700.00 from $1,150.00 previously

      4/28/25 8:33:23 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Eli Lilly with a new price target

      Cantor Fitzgerald initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $975.00

      4/22/25 7:32:42 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on Eli Lilly with a new price target

      BofA Securities resumed coverage of Eli Lilly with a rating of Buy and set a new price target of $997.00

      12/10/24 8:30:11 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation

      INDIANAPOLIS and WEST LAFAYETTE, Ind., May 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years. This partnership, which has the potential to be the largest ever industry-academic agreement of its kind in the United States, will seek to accelerate innovation at every stage of the pharmaceutical pipeline. The Lilly-Purdue 360 Initiative aims to achieve several key goals, including discovering and accelerating the delivery of medicines to patients; bridging the gap between laboratory discoveries a

      5/9/25 8:00:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly announces transitions in executive leadership

      INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced executive leadership transitions that will further enhance the company's ability to drive sustained, long-term growth and ensure that its medicines continue to reach millions of people worldwide.Lilly has experienced significant growth over the past several years, particularly in the U.S. and cardiometabolic health businesses. The company anticipates continued growth in these areas, along with further pipeline advancement. To help drive this next wave of growth, Lilly is increasing its leadership focus on the U.S. business and global therapeutic areas. Ilya Yuffa, executive vice president and president

      5/8/25 6:45:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly declares second-quarter 2025 dividend

      INDIANAPOLIS, May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries

      5/5/25 12:47:00 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      10/23/24 5:17:34 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      2/13/24 5:04:42 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      1/26/24 4:25:45 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Leadership Updates

    Live Leadership Updates

    See more

    $LLY
    Financials

    Live finance-specific insights

    See more

    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board

      Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS). ASHA-624 was designed using Asha's proprietary PRISM™ drug design technology, which creates new medicines to restore normal biology and provide functional cu

      11/13/24 9:30:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly appoints Lucas Montarce as executive vice president and chief financial officer

      INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately. Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health. He most recently served in the role of Lilly president and general manage

      9/9/24 6:45:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly announces retirement of Marschall S. Runge from its Board of Directors

      INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that Marschall S. Runge, M.D., Ph.D. is retiring from his role as an independent director of Lilly's board of directors effective Aug. 31, 2024. Dr. Runge has served on Lilly's board since 2013, including as a member of the board's Science and Technology Committee and Ethics and Compliance Committee. He is currently the CEO of Michigan Medicine, executive vice president for medical affairs at the University of Michigan and dean of the Medical School, and he plans to retire on June 30, 2025. Following retirement from these leadership roles, Dr. Runge will remain on the Medical School faculty as a prof

      8/16/24 4:15:00 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly declares second-quarter 2025 dividend

      INDIANAPOLIS, May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries

      5/5/25 12:47:00 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly reports first-quarter 2025 financial results and highlights pipeline momentum

      Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral GLP-1 agonist) in Type 2 diabetes in the first of seven obesity and diabetes Phase 3 trials.Q1 2025 EPS increased 23% to $3.06 on a reported basis and increased 29% to $3.34 on a non-GAAP basis, both inclusive of $1.72 of acquired IPR&D charges.Revenue guidance reaffirmed to be between $58.0 billion and $61.0 billion. INDIANAPOLIS, May 1, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025. "Lilly had a solid start to the year

      5/1/25 6:45:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • May 31, 2024 - FDA Roundup: May 31, 2024

      For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

      5/31/24 3:22:42 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 7, 2024 - FDA Roundup: May 7, 2024

      For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

      5/7/24 4:10:24 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • December 5, 2023 - FDA Roundup: December 5, 2023

      For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

      12/5/23 5:00:21 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care